BACKGROUND: Recurrent mutations in the promoter region of TERT (telomerase reverse transcriptase) have been found in various cancers including diffuse gliomas. Mutations lead to TERT upregulation and are associated with aggressive clinical behaviour in glioblastomas. However, the prognostic impact of TERT promoter mutations in lower grade gliomas remains undetermined. METHODS: The aim of this study is to evaluate the status of TERT promoter and the respective clinical significance in a cohort of 181 lower grade gliomas comprising grades II and III astrocytomas, oligodendrogliomas and oligoastrocytomas. RESULTS: Mutually exclusive mutations in TERT promoter, C228T and C250T, were identified in 12/89 (14%) diffuse astrocytomas, 8/23 (35%) anaplastic astrocytomas, 13/18 (72%) oligodendrogliomas, 3/3 (100%) anaplastic oligodendrogliomas, 17/45 (38%)

